|
Access to and use of this Web site are subject to the following conditions. Please do not use this Web site unless you agree with these conditions. This Web site has been developed by Talecris Biotherapeutics, Inc. (hereinafter to be referred to as TALECRIS) and is administrated by the same. We reserve the right to discontinue or to make partial or complete modifications to this Web site or to the General Conditions of Use or to our Privacy Statement. Please note that we may make such changes at our own discretion and without prior announcement. We must therefore ask you, next time you visit this Web site, to view the conditions again and to note any changes or amendments that may have been made.
Surrender of use and benefit
All details, documents and illustrations published on this Web site are the sole property of TALECRIS. Any permission to use the same is granted on the proviso that the relevant copyright note is displayed on all copies, that such details are only used for personal purposes, that they are not exploited commercially, that the details are not modified in any way and that all illustrations gained from the Web site are only used in conjunction with the accompanying text.
Trademarks and Copyright
All trademarks on this Web site are the property of TALECRIS, unless otherwise noted or in any other way perceivable as third party rights. Any unauthorized use of these trademarks or other materials is expressly prohibited and constitutes a violation of copyright, trademark law or other industrial property rights.
Limited liability
TALECRIS has compiled the detailed information provided on this Web site from internal and external sources to the best of its knowledge and belief, using professional diligence. We endeavor to expand and update this range of information on an ongoing basis. The information on this Web site is purely for the purpose of presenting TALECRIS and its products and services. However, no representation is made or warranty given, either expressly or tacitly, for the completeness or correctness of the information on this Web site. In particular, we must ask you to be aware that this information may no longer be up to date. We therefore recommend that you check any information you obtain from this Web site prior to using it in whatever form. Advice given on this Web site does not exempt you from conducting your own checks on our latest advice — particularly our safety datasheets and technical specifications — and on our products, with a view to their suitability for the intended processes and purposes. Should you require any advice or instructions concerning our products or services, please contact us directly. Users of this Web site declare that they agree to access the Web site and its content at their own risk. Neither TALECRIS nor third parties involved in the writing, production or transmission of this Web site can be held liable for damage or injury resulting from access or the impossibility of access or from the use or impossibility of use of this Web site or from the fact that you have relied on information given on this Web site
Web sites of third-party vendors/links
This Web site contains links/references to third-party Web sites. By providing such links, TALECRIS does not give its approval to their contents. Neither does TALECRIS accept any responsibility for the availability or the contents of such Web sites or any liability for damage or injury resulting from the use of such contents, of whatever form. Links to other Web sites are provided to Web site users merely for the sake of convenience. Users access such Web sites at their own risk.
Details supplied by yourself
The user of this Web site is fully responsible for the content and correctness of details he or she sends to TALECRIS as well as for the non-violation of any third-party rights that may be involved in such details. The user gives his or her consent for TALECRIS to store such details and to use the same for the purpose of statistical analysis or for any other specified business purpose, unless the information involves personal details, going beyond master data or usage data. In particular, TALECRIS is entitled to use the contents of such messages, including ideas, inventions, blueprints, techniques and expertise contained therein, for any purpose, such as the development, production and/or marketing of products or services and to reproduce such information and make it available to third parties without any limitations.
International users
This Web site is checked, operated and updated by Talecris Biotherapeutics, Inc. at Research Triangle Park, North Carolina (USA). TALECRIS gives no guarantee that the details presented on this Web site are also correct in places outside the USA, and, in particular, that products and services will be available with the same appearance, in the same sizes or on the same conditions. Should you call up this Web site from a place outside the USA or download contents from such a place, please note that it is your own responsibility to ensure that you act in compliance with local legislation applicable in that place.
Products mentioned on this Web site may come in different packaging, in different package sizes, or with different lettering or markings, depending on the country.
Site with login: access rights
Please note that you are obliged to protect your access rights from unauthorized third-party use and that you must ensure that they cannot be used by others without your authorization. You must notify TALECRIS immediately if you learn that security has been violated in respect of any details available on the TALECRIS Web site or if unauthorized persons have obtained your access rights or if you have found indications that such access might become possible.
Updated October 2006
Important Safety Information
Prolastin®, Alpha1-Proteinase Inhibitor (Human) is indicated for chronic replacement therapy of individuals having congenital deficiency of alpha-1 PI (alpha1-antitrypsin deficiency) with clinically demonstrable panacinar emphysema. Weekly Prolastin® therapy has demonstrated a low occurrence of side effects. In clinical studies with Prolastin®, reactions were observed in 1.16% of infusions, the most common events being fever (0.77%), light-headedness (0.19%), and dizziness (0.19%). As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated. Individuals with selective IgA deficiencies who have known antibody against IgA (anti-IgA antibody) should not receive Prolastin®, since these patients may experience severe reactions, including anaphylaxis, to IgA which may be present.
You are encouraged to report negative side effects of prescription drugs
to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please click here for Prolastin® full Prescribing Information.
Remember, your doctor or healthcare provider is the single best source of information regarding you and your health. Please consult your doctor or healthcare provider if you have any questions about your health or any of your medications.
|